Evidence map›Paper›PMID 35736278›Full record

ArticleMembranes2022

Virucidal and Bactericidal Filtration Media from Electrospun Polylactic Acid Nanofibres Capable of Protecting against COVID-19.

Fabrice Noël Hakan Karabulut, Dhevesh Fomra, Günther Höfler, Naveen Ashok Chand, Gareth Wesley Beckermann

Abstract read
In one paragraph

Article in Membranes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Advanced Self-Cleaning Surfaces.Materials (Basel, Switzerland) · 2024
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fabrice Noël Hakan KarabulutNanoLayr Ltd., 59 Mahunga Drive, Mangere Bridge, Auckland 2022, New Zealand.ORCID 0000-0003-3326-7986
Dhevesh FomraNanoLayr Ltd., 59 Mahunga Drive, Mangere Bridge, Auckland 2022, New Zealand.
Günther HöflerNanoLayr Ltd., 59 Mahunga Drive, Mangere Bridge, Auckland 2022, New Zealand.
Naveen Ashok ChandNanoLayr Ltd., 59 Mahunga Drive, Mangere Bridge, Auckland 2022, New Zealand.
Gareth Wesley BeckermannNanoLayr Ltd., 59 Mahunga Drive, Mangere Bridge, Auckland 2022, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Electrospun nanofibres excel at air filtration owing to diverse filtration mechanisms, thereby outperforming meltblown fibres. In this work, we present an electrospun polylactide acid nanofibre filter media, FilterLayrTM Eco, displaying outstanding bactericidal and virucidal properties using Manuka oil. Given the existing COVID-19 pandemic, face masks are now a mandatory accessory in many countries, and at the same time, they have become a source of environmental pollution. Made by NanoLayr Ltd., FilterLayrTM Eco uses biobased renewable raw materials with products that have end-of-life options for being industrially compostable. Loaded with natural and non-toxic terpenoid from manuka oil, FilterLayr Eco can filter up to 99.9% of 0.1 µm particles and kill >99% of trapped airborne fungi, bacteria, and viruses, including SARS-CoV-2 (Delta variant). In addition, the antimicrobial activity, and the efficacy of the filter media to filtrate particles was shown to remain highly active following several washing cycles, making it a reusable and more environmentally friendly option. The new nanofibre filter media, FilterLayrTM Eco, met the particle filtration efficiency and breathability requirements of the following standards: N95 performance in accordance with NIOSH 42CFR84, level 2 performance in accordance with ASTM F2100, and level 2 filtration efficiency and level 1 breathability in accordance with ASTM F3502. These are globally recognized facemask and respirator standards.

Indexed as

electrospunfilter mediafiltrationnanofibrepolylactid acidSARS-CoV-2

Identifiers

PMID35736278
PMCPMC9227935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.